package protobuf.opencb

Mouse Melon logoGet desktop application:
View/edit binary Protocol Buffers messages

enum AlleleOrigin

evidence.proto:384

* Variant origin. `SO_0001781`: de novo variant. http://purl.obolibrary.org/obo/SO_0001781 `SO_0001778`: germline variant. http://purl.obolibrary.org/obo/SO_0001778 `SO_0001775`: maternal variant. http://purl.obolibrary.org/obo/SO_0001775 `SO_0001776`: paternal variant. http://purl.obolibrary.org/obo/SO_0001776 `SO_0001779`: pedigree specific variant. http://purl.obolibrary.org/obo/SO_0001779 `SO_0001780`: population specific variant. http://purl.obolibrary.org/obo/SO_0001780 `SO_0001777`: somatic variant. http://purl.obolibrary.org/obo/SO_0001777

Used in: EvidenceEntry

message AlternateCoordinate

variant.proto:183

Used in: StudyEntry, VcfRecord

message BasicRequest

service_types.proto:8

message Breakend

variant.proto:288

Used in: StructuralVariation

message BreakendMate

variant.proto:281

Used in: Breakend

enum BreakendOrientation

variant.proto:274

SE | (Start -> End) | s | t[p[ | piece extending to the right of p is joined after t SS | (Start -> Start) | s | t]p] | reverse comp piece extending left of p is joined after t ES | (End -> Start) | s | ]p]t | piece extending to the left of p is joined before t EE | (End -> End) | s | [p[t | reverse comp piece extending right of p is joined before t

Used in: Breakend

message CancerHotspotAlternateAnnotation

variant_annotation.proto:233

Used in: CancerHotspotVariantAnnotation

message CancerHotspotVariantAnnotation

variant_annotation.proto:239

Used in: VariantAnnotation

enum ClinicalSignificance

evidence.proto:167

* Mendelian variants classification with ACMG terminology as defined in Richards, S. et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–423. https://doi.org/10.1038/gim.2015.30. Classification for pharmacogenomic variants, variants associated to disease and somatic variants based on the ACMG recommendations and ClinVar classification (https://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/). `benign_variant` : Benign variants interpreted for Mendelian disorders `likely_benign_variant` : Likely benign variants interpreted for Mendelian disorders with a certainty of at least 90% `pathogenic_variant` : Pathogenic variants interpreted for Mendelian disorders `likely_pathogenic_variant` : Likely pathogenic variants interpreted for Mendelian disorders with a certainty of at least 90% `uncertain_significance` : Uncertain significance variants interpreted for Mendelian disorders. Variants with conflicting evidences should be classified as uncertain_significance

Used in: VariantClassification

enum Confidence

evidence.proto:402

* Confidence based on the Confidence Information Ontology `CIO_0000029`: high confidence level http://purl.obolibrary.org/obo/CIO_0000029 `CIO_0000031`: low confidence level http://purl.obolibrary.org/obo/CIO_0000031 `CIO_0000030`: medium confidence level http://purl.obolibrary.org/obo/CIO_0000030 `CIO_0000039`: rejected http://purl.obolibrary.org/obo/CIO_0000039

Used in: EvidenceEntry

message ConsequenceType

variant_annotation.proto:77

Used in: VariantAnnotation

enum ConsistencyStatus

evidence.proto:420

* The consistency of evidences for a given phenotype. This aggregates all evidences for a given phenotype and all evidences with no phenotype associated (e.g.: in silico impact prediction, population frequency). This is based on the Confidence Information Ontology terms. `CIO_0000033`: congruent, all evidences are consistent. http://purl.obolibrary.org/obo/CIO_0000033 `CIO_0000034`: conflict, there are conflicting evidences. This should correspond to a `VariantClassification` of `uncertain_significance` for mendelian disorders. http://purl.obolibrary.org/obo/CIO_0000034 `CIO_0000035`: strongly conflicting. http://purl.obolibrary.org/obo/CIO_0000035 `CIO_0000036`: weakly conflicting. http://purl.obolibrary.org/obo/CIO_0000036

Used in: EvidenceEntry

message Constraint

variant_annotation.proto:131

Used in: VariantAnnotation

message Cytoband

variant_annotation.proto:113

Used in: VariantAnnotation

message Drug

variant_annotation.proto:121

Used in: VariantAnnotation

enum DrugResponseClassification

evidence.proto:187

* Pharmacogenomics drug response variant classification `responsive` : A variant that confers response to a treatment `resistant` : A variant that confers resistance to a treatment `toxicity` : A variant that is associated with drug-induced toxicity `indication` : A variant that is required in order for a particular drug to be prescribed `contraindication` : A variant that if present, a particular drug should not be prescribed `dosing` : A variant that results in an alteration in dosing of a particular drug in order to achieve INR, reduce toxicity or increase efficacy `increased_monitoring` : increase vigilance or increased dosage monitoring may be required for a patient with this variant to look for signs of adverse drug reactions `efficacy` : a variant that affects the efficacy of the treatment

Used in: VariantClassification

enum EthnicCategory

evidence.proto:326

* This is the list of ethnics in ONS16 `D`: Mixed: White and Black Caribbean `E`: Mixed: White and Black African `F`: Mixed: White and Asian `G`: Mixed: Any other mixed background `A`: White: British `B`: White: Irish `C`: White: Any other White background `L`: Asian or Asian British: Any other Asian background `M`: Black or Black British: Caribbean `N`: Black or Black British: African `H`: Asian or Asian British: Indian `J`: Asian or Asian British: Pakistani `K`: Asian or Asian British: Bangladeshi `P`: Black or Black British: Any other Black background `S`: Other Ethnic Groups: Any other ethnic group `R`: Other Ethnic Groups: Chinese `Z`: Not stated

Used in: EvidenceEntry

message EvidenceEntry

evidence.proto:477

* An entry for an evidence

Used in: VariantAnnotation

enum EvidenceImpact

evidence.proto:297

* Evidence of pathogenicity and benign impact as defined in Richards, S. et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–423. https://doi.org/10.1038/gim.2015.30 Evidence of pathogenicity: `very_strong`: - PVS1 null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease `strong`: - PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide change - PS2 De novo (both maternity and paternity confirmed) in a patient with the disease and no family history - PS3 Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product - PS4 The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls `moderate`: - PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation - PM2 Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium - PM3 For recessive disorders, detected in trans with a pathogenic variant - PM4 Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants - PM5 Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before - PM6 Assumed de novo, but without confirmation of paternity and maternity `supporting`: - PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease - PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease - PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.) - PP4 Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology - PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation Evidence of benign impact: `stand_alone`: - BA1 Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium `strong`: - BS1 Allele frequency is greater than expected for disorder - BS2 Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age - BS3 Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing - BS4 Lack of segregation in affected members of a family `supporting`: - BP1 Missense variant in a gene for which primarily truncating variants are known to cause disease - BP2 Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern - BP3 In-frame deletions/insertions in a repetitive region without a known function - BP4 Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.) - BP5 Variant found in a case with an alternate molecular basis for disease - BP6 Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation - BP7 A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved

Used in: EvidenceEntry

message EvidenceSource

evidence.proto:13

* The source of an evidence.

Used in: EvidenceEntry

message EvidenceSubmission

evidence.proto:31

* The submission information

Used in: EvidenceEntry

message Exon

transcript.proto:29

Used in: Transcript

message ExonOverlap

variant_annotation.proto:66

Used in: ConsequenceType

message Expression

common.proto:16

Used in: GeneAnnotation, VariantAnnotation

enum ExpressionCall

common.proto:11

Used in: Expression

enum FeatureTypes

evidence.proto:124

* The feature types

Used in: GenomicFeature

message Fields

vcf_record.proto:46

Used in: VcfSlice

message FileEntry

variant.proto:177

Used in: StudyEntry

message Gene

gene.proto:48

message GeneAnnotation

gene.proto:42

Used in: Gene

message GeneCancerAssociation

variant_annotation.proto:144

Used in: VariantAnnotation

message GeneDrugInteraction

common.proto:27

Used in: GeneAnnotation, VariantAnnotation

message GeneFusionBreakpoint

variant_annotation.proto:289

Used in: GeneFusionSummary

message GeneFusionSummary

variant_annotation.proto:296

Used in: VariantAnnotation

message GeneImprinting

variant_annotation.proto:281

Used in: VariantAnnotation

message GeneMirnaTarget

variant_annotation.proto:138

Used in: VariantAnnotation

message GeneTraitAssociation

gene.proto:31

Used in: GeneAnnotation, VariantAnnotation

message GenomicFeature

evidence.proto:134

* The genomic feature

Used in: EvidenceEntry

message GenomicSequenceContext

variant_annotation.proto:310

Used in: VariantAnnotation

message GroupResponse

service_types.proto:34

message GwasAssociation

variant_annotation.proto:224

Used in: VariantAnnotation

message GwasAssociationStudy

variant_annotation.proto:213

Used in: GwasAssociation

message GwasAssociationStudyTrait

variant_annotation.proto:206

Used in: GwasAssociationStudy

message GwasAssociationStudyTraitScores

variant_annotation.proto:189

Used in: GwasAssociationStudyTrait

message HeritableTrait

evidence.proto:110

* The entity representing a phenotype and its inheritance pattern.

Used in: EvidenceEntry

message IssueEntry

variant.proto:210

Used in: StudyEntry

enum IssueEntry.IssueType

variant.proto:212

Used in: IssueEntry

message LongResponse

service_types.proto:19

message MapResponse

service_types.proto:39

message MiRNAGene

gene.proto:14

Used in: Gene

message MiRNAGene.MiRNAMature

gene.proto:22

Used in: MiRNAGene

enum ModeOfInheritance

evidence.proto:92

* An enumeration for the different mode of inheritances: `monoallelic_not_imprinted`: MONOALLELIC, autosomal or pseudoautosomal, not imprinted `monoallelic_maternally_imprinted`: MONOALLELIC, autosomal or pseudoautosomal, maternally imprinted (paternal allele expressed) `monoallelic_paternally_imprinted`: MONOALLELIC, autosomal or pseudoautosomal, paternally imprinted (maternal allele expressed) `monoallelic`: MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown `biallelic`: BIALLELIC, autosomal or pseudoautosomal `monoallelic_and_biallelic`: BOTH monoallelic and biallelic, autosomal or pseudoautosomal `monoallelic_and_more_severe_biallelic`: BOTH monoallelic and biallelic, autosomal or pseudoautosomal (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal `xlinked_biallelic`: X-LINKED: hemizygous mutation in males, biallelic mutations in females `xlinked_monoallelic`: X linked: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males) `mitochondrial`: MITOCHONDRIAL `unknown`: Unknown `NA`: Not applicable

Used in: HeritableTrait

message OntologyTermAnnotation

variant_annotation.proto:197

Used in: GwasAssociationStudyTrait, PolygenicScoreAnnotation

message OriginalCall

variant.proto:164

Used in: FileEntry

enum Penetrance

evidence.proto:349

* Penetrance assumed in the analysis

Used in: EvidenceEntry

message Pharmacogenomics

variant_annotation.proto:179

Used in: VariantAnnotation

message PharmacogenomicsAlleles

variant_annotation.proto:160

Used in: PharmacogenomicsClinicalAnnotation

message PharmacogenomicsClinicalAnnotation

variant_annotation.proto:166

Used in: Pharmacogenomics

message PolygenicScoreAnnotation

variant_annotation.proto:270

Used in: VariantAnnotation

message PolygenicScoreVariant

variant_annotation.proto:260

Used in: PolygenicScoreAnnotation

message PopulationFrequency

variant_annotation.proto:15

Used in: VariantAnnotation

message Property

evidence.proto:432

* A property in the form of name-value pair. Names are restricted to ontology ids, they should be checked against existing ontologies in resources like Ontology Lookup Service.

Used in: EvidenceEntry

message ProteinFeature

variant_annotation.proto:38

Used in: ProteinVariantAnnotation

message ProteinVariantAnnotation

variant_annotation.proto:52

Used in: ConsequenceType

message PubmedReference

variant_annotation.proto:252

Used in: PolygenicScoreAnnotation

message RegulatoryRegion

regulatory_region.proto:10

message Repeat

variant_annotation.proto:99

Used in: VariantAnnotation

message Response

service_types.proto:13

Used in: GroupResponse, LongResponse, MapResponse, StringArrayResponse, StringResponse

message SampleEntry

variant.proto:204

Used in: IssueEntry, StudyEntry

message Score

variant_annotation.proto:46

Used in: ProteinVariantAnnotation, VariantAnnotation

message SequenceOntologyTerm

variant_annotation.proto:33

Used in: ConsequenceType

message SomaticInformation

evidence.proto:49

* The somatic information.

Used in: EvidenceEntry

message SpliceScores

variant_annotation.proto:72

Used in: ConsequenceType

message StringArrayResponse

service_types.proto:29

message StringMap

variant_annotation.proto:266

Used in: PolygenicScoreAnnotation

message StringResponse

service_types.proto:24

message StructuralVariation

variant.proto:295

Used in: Variant

enum StructuralVariation.StructuralVariantType

variant.proto:304

* Type of structural variation <ul> <li>COPY_NUMBER_GAIN for CNVs</li> <li>COPY_NUMBER_LOSS for CNVs</li> <li>TANDEM_DUPLICATION for DUP</li> </ul>

Used in: StructuralVariation

message StudyEntry

variant.proto:251

Used in: Variant

enum TraitAssociation

evidence.proto:216

* Association of variants to a given trait. `established_risk_allele` : Established risk allele for variants associated to disease `likely_risk_allele` : Likely risk allele for variants associated to disease `uncertain_risk_allele` : Uncertain risk allele for variants associated to disease `protective` : Protective allele

Used in: VariantClassification

message Transcript

transcript.proto:46

Used in: Gene

message TranscriptTfbs

transcript.proto:17

Used in: Transcript

enum TumorigenesisClassification

evidence.proto:229

* Variant classification according to its relation to cancer aetiology. `driver` : Driver variants `passenger` : Passenger variants `modifier` : Modifier variants

Used in: VariantClassification

message Variant

variant.proto:336

message VariantAnnotation

variant_annotation.proto:316

Used in: Variant

message VariantAnnotation.AdditionalAttribute

variant_annotation.proto:359

Used in: VariantAnnotation

message VariantAnnotation.Xref

variant_annotation.proto:325

Used in: VariantAnnotation

message VariantClassification

evidence.proto:451

* The variant classification according to different properties.

Used in: EvidenceEntry

message VariantFileMetadata

variant.proto:422

enum VariantFunctionalEffect

evidence.proto:364

* Variant effect with Sequence Ontology terms. `SO_0002052`: dominant_negative_variant (http://purl.obolibrary.org/obo/SO_0002052) `SO_0002053`: gain_of_function_variant (http://purl.obolibrary.org/obo/SO_0002053) `SO_0001773`: lethal_variant (http://purl.obolibrary.org/obo/SO_0001773) `SO_0002054`: loss_of_function_variant (http://purl.obolibrary.org/obo/SO_0002054) `SO_0001786`: loss_of_heterozygosity (http://purl.obolibrary.org/obo/SO_0001786) `SO_0002055`: null_variant (http://purl.obolibrary.org/obo/SO_0002055)

Used in: VariantClassification

message VariantScore

variant.proto:227

Used in: StudyEntry

message VariantStats

variant.proto:51

Used in: StudyEntry

enum VariantType

variant.proto:22

* Type of variation, which depends mostly on its length. <ul> <li>SNVs involve a single nucleotide, without changes in length</li> <li>MNVs involve multiple nucleotides, without changes in length</li> <li>Indels are insertions or deletions of less than SV_THRESHOLD (50) nucleotides</li> <li>Structural variations are large changes of more than SV_THRESHOLD nucleotides</li> <li>Copy-number variations alter the number of copies of a region</li> </ul>

Used in: AlternateCoordinate, Variant, VcfRecord

message VcfRecord

vcf_record.proto:19

Used in: VcfSlice

message VcfSample

vcf_record.proto:12

Used in: VcfRecord

message VcfSlice

vcf_record.proto:64

message Xref

transcript.proto:10

Used in: Transcript